高强度聚焦超声消融联合化疗治疗局部晚期胰腺癌的倾向性评分匹配分析
该回顾性研究纳入254例不可切除局部晚期胰腺癌患者,其中92例接受HIFU消融联合化疗。
要点
- HIFU联合吉西他滨化疗可改善不可切除局部晚期胰腺癌的总生存期。
- HIFU组客观缓解率高于单纯化疗组,且安全性可控。
- NRS<4且接受HIFU消融的患者总生存期改善更显著。
英文原文(摘要)· 点击展开
OBJECTIVES: This retrospective study was conducted to assess the efficacy and safety of high intensity focused ultrasound (HIFU) in combination with chemotherapy compared with chemotherapy alone in treating patients with unresectable locally advanced pancreatic cancer (LAPC).
METHODS: The data of unresectable LAPC patients who received chemotherapy with or without HIFU ablation were retrieved retrospectively. The overall survival (OS), objective response rate (ORR), cancer antigen 19-9 response rate, and safety were compared between these two groups before and after propensity score matching (PSM).
RESULTS: Overall, 254 patients with LAPC were included, of whom 92 underwent HIFU ablation. After PSM to control for potential biases, HIFU was associated with improved OS (12.8 versus 12.2 months, log-rank P = .046), as compared to patients without HIFU ablation. Patients with numeric rating scale (NRS) less than 4, and receiving HIFU ablation were significantly associated with improved OS (adjusted hazard ratio [aHR] = 0.365 [95% confidence interval (CI) = 0.148-0.655], P = .002; aHR = 0.490 [95% CI = 0.250-0.961], P = .038; respectively) by multivariate analyses with the adjustment of age, NRS, and tumor size. ORR was also observed to be higher in HIFU group of 30.0% than in the chemotherapy group of 13.3% (P = .039). No severe adverse events of special interest or HIFU-caused deaths were observed.
CONCLUSIONS: Patients with unresectable LAPC who received gemcitabine-based chemotherapy might benefit from additional HIFU ablation.
引用
- Ning, Wang, Guo, et al. High Intensity Focused Ultrasound Ablation for Patients With Locally Advanced Pancreatic Adenocarcinoma: A Propensity Score-Matching Analysis. J Ultrasound Med. 2023. PMID: 36691925. doi:10.1002/jum.16181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。